Continuing Progress in Vasculitis Research

Abstracts of the 17th International Vasculitis & ANCA Workshop
London, April 19–22, 2015

Guest Editors
Charles D. Pusey, London
Alan D. Salama, London
Disclosure Statement Guest Editors

The guest editors declare no conflict of interest.

The 17th International Vasculitis & ANCA Workshop and this supplement issue were sponsored by:

**Diamond Sponsor:** Roche Products Limited

**Gold Sponsor:** Terumo BCT

**Silver Sponsor:** ChemoCentryx, Inc.

**Exhibitors:**

- Bristol-Myers Squibb UK
- Euroimmun AG
- Kidney Research UK
- The Lauren Currie Twilight Foundation
- Vasculitis Foundation
- Vasculitis UK

The organisers of the 17th International Vasculitis & ANCA Workshop are grateful to Vasculitis UK for their donation towards the Workshop.

**Disclaimer**

The sponsors and exhibitors have had no input into the organisation, content or speaker selection relating to this Workshop.

**Drug Dosage**

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see ‘General Information’).

© Copyright 2015 by S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland)
Contents

IV Scientific Programme and Organising Committees
V Introduction
VI Programme
1 Extended Abstracts
45 Abstracts
250 Author Index
# Scientific Programme and Organising Committees

## Chairmen
- Charles Pusey (London)
- Alan Salama (London)

## Local Organising Committee
- Neil Basu (Aberdeen)
- Paul Brogan (London)
- Terry Cook (London)
- Lorraine Harper (Birmingham)
- David Jayne (Cambridge)
- Mark Little (Dublin)
- Raashid Luqmani (Oxford)
- Justin Mason (London)
- John Mills (Derbyshire)
- Mike Robson (London)
- Ken Smith (Cambridge)
- Neil Turner (Edinburgh)
- Michael Venning (Manchester)
- Richard Watts (Ipswich)

## International Scientific Committee
- Paul Bacon (UK)
- Ingeborg Bajema (Netherlands)
- Bo Basland (Denmark)
- Leonard Calabrese (USA)
- Min Chen (China)
- Maria Cid (Spain)
- Kirsten de Groot (Germany)
- Ron Falk (USA)
- Franco Ferrario (Italy)
- Luis Felipe Flores-Suarez (Mexico)
- Shouichi Fujimoto (Japan)
- Gina Gregorini (Italy)
- Wolfgang Gross (Germany)
- Loic Guilleuin (France)
- Marion Haubitz (Germany)
- Peter Heeringa (Netherlands)
- Gary Hoffman (USA)
- Julia Holle (Germany)
- Charles Jennette (USA)
- Cees Kallenberg (Netherlands)
- Ralph Kettritz (Germany)
- Richard Kitching (Australia)
- Peter Lamprecht (Germany)
- Carol Langford (USA)
- Alfred Mahr (France)
- Eric Matteson (USA)
- Peter Merkel (USA)
- Patrick Nachman (USA)
- Seza Ozen (Turkey)
- John Niles (USA)
- Christine Pagnoux (Canada)
- Niels Rasmussen (Denmark)
- Andy Rees (Austria)
- Caroline Savage (UK)
- Judy Savige (Australia)
- David Scott (UK)
- Marten Segelmark (Sweden)
- Alberto Sinico (Italy)
- Ulrich Specks (USA)
- Coen Stegeman (Netherlands)
- John Stone (USA)
- Kazuo Suzuki (Japan)
- Jan-Willem Cohen Tervaert (Netherlands)
- Vladimir Tesar (Czech Republic)
- Michael Walsh (Canada)
- Kerstin Westman (Sweden)
- Cornelia Weyand (USA)
- Jorgen Wieslander (Sweden)
- Veronique Witko-Sarsat (France)
- Ming-Hui Zhao (China)
Continuing Progress in Vasculitis Research

Since many forms of systemic vasculitis are rare, it is perhaps remarkable that so much progress has been made in understanding pathogenesis and developing new protocols for treatment over the last few decades. For small vessel vasculitis, this was undoubtedly catalysed by the discovery of anti-neutrophil cytoplasm antibodies (ANCA) 30 years ago. The community of vasculitis researchers and clinicians has developed during this time, such that medium and large vessel vasculitis have also benefited from increased research activity.

The Vasculitis and ANCA Workshops held approximately every two years, have been integral to the development of the understanding of these diseases. We are now looking forward to the 17th Workshop in 2015, which coincides with the 30th anniversary of the publication of one of the most important papers in the field, by Fokko van der Woude and colleagues. This work led onto the development of the European Vasculitis Study Group, now the European Vasculitis Society. In parallel, the Vasculitis Clinical Research Consortium has developed in the USA. Through these organisations and other national bodies interested in vasculitis, we now have a truly international network of centres collaborating on basic research and clinical trials in the field of systemic vasculitis.

Although the initial focus of these Workshops was on ANCA-associated vasculitis, there has been a progressive increase in the number of contributions related to other forms of primary and secondary vasculitis. This trend will be continued at the 17th Workshop, which will bring together clinical and basic research in all types of vasculitis, and involve researchers and clinicians from the many specialties involved in looking after these patients.

Over 340 abstracts have been accepted for the 17th Workshop, highlighting the tremendous activity in the field. These presentations include a full range of basic and clinical research in small and large vessel vasculitis, including epidemiology, genetics, autoimmunity, inflammation, biomarkers, diagnostic techniques and new approaches to treatment, including the benefit and complications of biological agents. Importantly, for the first time, the role of patient involvement and engagement will also be covered. This is particularly relevant, since with the development of better forms of treatment many types of vasculitis have become chronic relapsing diseases, in which the quality of life of the patients is a high priority.

Despite the significant advances over the last few decades, it is clear that we still have a lot to learn about the causes and optimal treatment of vasculitis. We hope that the presentations and discussions at the forthcoming Workshop will serve as a platform to improve the management of systemic vasculitis for the benefit of our patients.

Charles D. Pusey, London
Alan D. Salama, London

Vasculitis and ANCA Workshops

1. 1988 Copenhagen (A. Wiik, N. Rasmussen)
2. 1989 Noordwijk (F. van der Woude, C. Kallenberg)
3. 1990 Washington, DC (C. Jennette, R. Falk)
4. 1992 Lübeck (W. Gross)
5. 1993 Cambridge (M. Lockwood, C. Pusey)
6. 1995 Paris (P. Lesavre, L.H. Noël)
7. 1996 Rochester (R. DeReeme)
8. 1998 Birmingham (P. Bacon)
10. 2002 Cleveland (G. Hoffman, L. Calabrese)
11. 2003 Prague (V. Tesar)
12. 2005 Heidelberg (K. Andrassy)
13. 2007 Cancun (L.F. Flores-Suárez)
14. 2009 Lund-Copenhagen (M. Segelmark, N. Rasmussen)
15. 2011 Chapel Hill (R. Falk, C. Jennette)
16. 2013 Paris (L. Guillemin)
17. 2015 London (C. Pusey, A. Salama)
### Programme

**17th International Vasculitis & ANCA Workshop**  
19–22 April 2015  
Business Design Centre, Islington, London

**SUNDAY 19 APRIL**

16:50–17:00 (Auditorium)  
Welcome – Charles Pusey  
17:00–18:00  
**FOKKO VAN DER WOUDE LECTURE**  
Chairs: Charles Pusey & Alan Salama  
Andrew Rees “Small Vessel Vasculitis – To ANCA and Beyond”

18:00–19:00  
**WELCOME RECEPTION** (Gallery Hall)

**MONDAY 20 APRIL**

08:00–09:30  
**Javier Martín** “Genetic Analysis of Large Vessel Vasculitis”  
08:30–09:00  
**Kenneth Smith** “Genetics of Small Vessel Vasculitis”

09:00–09:15  
**O1: A. Sawalha** “Genome-Wide Association Study Identifies Novel Genetic Susceptibility Loci in Takayasu’s Arteritis”  
09:15–09:30  
**O2: B. Erer** “CECR1 p.Gly47Arg Mutations Are Not Increased in Frequency in Turkish Behçet’s Disease Patients Compared with Healthy Controls”

09:30–09:45  
**O3: J. Yang** “Longitudinal Investigation of a Large Inception Cohort of Patients with ANCA Vasculitis Reveals That Increased PR3 and MPO Expression Correlates with Disease Activity”  
09:45–10:00  
**O4: T. Oates** “DNA Methylation Differences at Gene Regulatory Elements Are Associated with Disease Susceptibility in a Rat Model of Crescentic Glomerulonephritis”

10:00–10:30  
**TEA/COFFEE**

10:30–12:15: **PARALLEL SESSION 1 (Auditorium)**  
**PATIENT PRIORITIES**  
Chairs: Lorraine Harper & Michael Venning

10:30–11:00  
**Neil Basu** “Patient Priorities in Vasculitis: A Physician’s Perspective”  
11:00–11:30  

11:30–11:45  
**O5: N. Brown** “Development of a Vasculitis Care Optimisation Tool (VasCOT), in Collaboration with Hitachi Europe”  
11:45–12:00  
**O6: G. Hatemi** “Predictors of Quality of Life in Behçet’s Syndrome”

11:30–11:45  
**O8: A. Schreiber** “Neutrophil-extracellular Traps Cause ANCA-Induced Glomerulonephritis in a Complement Dependent Manner and Is Controlled by the Necroptosis Pathway”  
11:45–12:00  
**O9: S. McAdoo** “The Role of Spleen Tyrosine Kinase (SYK) in the Pathogenesis of ANCA-Associated Vasculitis”

12:00–12:15  
**O10: B. Hu** “Bradykinin Receptors on Bone Marrow Derived Cells Are Important for Mediating ANCA Glomerulonephritis”  
12:00–12:15  
**O11: A. Tanna** “The Effect of Anti-BLyS Antibody in Experimental Autoimmune Vasculitis”

08:00–10:00: **PLENARY SESSION 1 (Auditorium)**  
**GENETICS AND EPIGENETICS**  
Chairs: Andrew Rees & Augusto Vaglio

10:30–12:15: **PARALLEL SESSION 2 (Room A)**  
**EXPERIMENTAL MODELS**  
Chairs: Mark Little & Peter Heeringa

10:30–11:00  
**Richard Kitching** “Recent Findings in Animal Models of MPO-ANCA Associated Glomerulonephritis”  
11:00–11:15  
**O8: A. Schreiber** “Neutrophil-extracellular Traps Cause ANCA-Induced Glomerulonephritis in a Complement Dependent Manner and Is Controlled by the Necroptosis Pathway”

11:30–11:45  
**O10: B. Hu** “Bradykinin Receptors on Bone Marrow Derived Cells Are Important for Mediating ANCA Glomerulonephritis”  
11:45–12:00  
**O11: A. Tanna** “The Effect of Anti-BLyS Antibody in Experimental Autoimmune Vasculitis”

12:00–12:15  
**O12: Q. Wang** “Effect of Ageing on Anti-MPO Antibody Mediated Glomerulonephritis in Mice”

© 2015 S. Karger AG, Basel  
E-Mail karger@karger.com  
www.karger.com/nef
10:30–12:15: PARALLEL SESSION 3 (Rooms B&C)
AUTOANTIBODIES IN VASCULITIS
Chairs: Kazuo Suzuki & Veronique Witko-Sarsat

10:30–11:00
Elena Csernok “The Spectrum of Autoantibodies Found in Systemic Vasculitides”

11:00–11:15
O13: E. Miloslavsky “Contribution of ANCA-Type and Disease Type to Clinical Manifestations and Outcomes in ANCA-Associated Vasculitis”

11:15–11:30
O14: M. Segelmak “Circulating IgA Class Anti-PR3 Antibodies in Relation to Organ Involvement and Disease Activity in PR3-ANCA Associated Vasculitis”

11:30–11:45
O15: M. Ball “Antibodies to the Bacterial Adhesin FimH: A Potential Trigger in ANCA Associated Vasculitis”

11:45–12:00
O16: A. Goceroglu “Presence of Anti-Plasminogen Antibodies in ANCA-Associated Vasculitis: Development of a New Assay”

12:00–12:15
O17: S. Holding “PR3/MPO-ANCA Is as Effective as Immunofluorescence as a First-Line Test in AAV Screening”

12:25–13:20
LUNCHTIME SYMPOSIUM sponsored by Terumo (Auditorium)
Patient Centred Therapy: Plasma Exchange and Immunomodulation
12:25–12:40 Alan Salama “Cross Specialty Approach, How to Improve Visibility of TPE Across Departments”

13:30–15:00: PLENARY SESSION 2 (Auditorium)
BIOMARKERS IN AAV
Chairs: David Jayne & Kirsten de Groot

13:30–14:00
Ron Falk “Biomarkers in ANCA Vasculitis – Trial and Tribulation”

14:00–14:15
O18: L.-P. Erwig “A Four Dimensional in vitro Model of Neutrophil/Monocyte-Endothelial Interactions to Define Novel Biomarkers of Disease Activity in Patients with ANCA Associated Vasculitis”

14:30–14:45
O20: Y. O’Reilly “Soluble CD163 Level as a Biomarker of Active Disease in Systemic Vasculitis”

14:15–14:30
O19: B. Terrier “Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy: Data from the Extended Follow-Up of MAINRITSAN Trial Patients”

14:45–15:00
O21: H. Wang “Is Circulating Level of Neutrophil Extracellular Traps a Biomarker in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis?”

15:00–16:00
POSTER SESSION 1
Moderated Posters P1–P28
Posters P57–P158

16:00–16:30
TEA/COFFEE

16:30–18:15: PARALLEL SESSION 4 (Auditorium)
SECONDARY VASCULITIS
Chairs: Carol Langford & Seza Ozen

16:30–17:00
Farida Fortune “Behçet’s Disease: An Overview of Pathogenesis, Clinical Presentation and Management”

17:00–17:15

17:15–17:30
O23: E. Seyahi “18 F-FDG PET/CT in Large Vessel Disease Due to in Behçet’s Disease: A Preliminary Report”

17:30–17:45
O24: S. Flint “Distinct Features of the Immune Phenotype of Behçet’s Disease as Compared with Inflammatory Bowel Disease, ANCA-Associated Vasculitis, Systemic Lupus Erythematosus and Healthy Volunteers”

17:45–18:00
O25: E.D. Batu “Adenosine Deaminase 2 (ADA2) Deficiency as a New Secondary Vasculitis with a Known Genetic Cause”

18:00–18:15
O26: C. Perugino “Large Vessel Involvement by IgG4-Related Disease: A Single Center Experience”

16:30–18:15: PARALLEL SESSION 5 (Room A)
REGISTRIES AND OUTCOMES
Chairs: Neil Hasu & Vladimir Tesar

16:30–17:00
Harry Hemingway “Pros and Cons of Disease Registries”

17:00–17:15
O27: A. Misroy “Cardiovascular Outcomes Are Worse in Microscopic Polyangitis Compared to Granulomatosis with Polyangiitis: Data from an Inception Cohort of Patients with Anti-Neutrophil Cytoplasm Antibody Associated Systemic Vasculitis”

17:15–17:30
O28: F. Pearce “Epidemiology of ANCA-Associated Vasculitis (AAV) in a Multi-Ethnic Urban Population”

17:30–17:45
O29: Z. Hruskova “Patients with Severe Renal ANCA-Associated Vasculitis: Characteristics and Long-Term Outcome – Data from a National Vasculitis Registry”

17:45–18:00
O30: G. Tomasson “The Association of Giant Cell Arteritis and Its Histopathology with All-Cause and Cardiovascular Mortality”

18:00–18:15
O31: J. Robson “Increased Risk of Cardiovascular and Cerebrovascular Outcomes in Patients with Giant Cell Arteritis Independently Associated with Social Deprivation”

16:30–18:10: PARALLEL SESSION 6 (Rooms B&C)
ORGAN SPECIFIC VASCULITIS
Chairs: Christian Pagnoux & Judy Savage

16:30–16:50
Susan Lightman “Systemic Vasculitis and the Eye – Recent Data from the Multidisciplinary Vasculitis Team at the Hammersmith Hospital”

16:50–17:10
Robert Hadden “Peripheral Nerve Involvement in Vasculitis”

17:10–17:25
O32: B. Terrier “Granulomatosis with Polyangiitis (Wegener’s): Endoscopic Management of Tracheobronchial Stenosis – Results from a Multicenter Experience in 47 Patients”

17:25–17:40
O33: W. Pendergraft III “In-Depth Analysis of Neurologic Complications of ANCA Vasculitis in a Large Inception Cohort Reveals Novel Associations”

17:40–17:55
O34: H. Wang “A 10-Year Retrospective Survey of Pachymeningitis in the Neurorimmunology Clinic”

17:55–18:10
O35: I. Kwame “The Significance of ENT Manifestations in ANCA Associated Vasculitis”
TUESDAY 21 APRIL

08:00–10:00: PLENARY SESSION 3 (Auditorium)
AUTOIMMUNITY IN AAV
Chairs: John Niles & Cees Kallenberg

08:00–08:30 Claudio Mauri “B Cells as Immune Regulators in Autoimmunity”

08:30–08:45 O36: Md Yusuf “Repeat Cycles on Clinical Relapse for Remission Maintenance in ANCA-Associated Vasculitis: Identifying B Cell Biomarkers to Guide Rituximab Re-Treatment Strategy”

08:45–09:00 O37: D. Bunch “Gleaning Relapse Risk from B Cell Phenotype: Decreased CD5+ B Cells Portend a Shorter Time to Relapse After B Cell Depletion in Patients with ANCA Vasculitis”

09:00–09:15 O38: M. Yoshida “Affinity of MPO-ANCA is Associated with the Formation of Neutrophil Extracellular Traps and with Vasculitis Activity in MPO-ANCA Associated Microscopic Polyangiitis”

09:15–09:30 O39: A. Tanna “Clinical Importance of Serum BlyS Levels in AAV”

09:30–09:45 O40: L. Lintermans “Phenotypic Analysis of CD4+ Effector Memory T-Cells (TEM) in Peripheral Blood of GPA Patients Demonstrates an Increased Proportion of CCR3+CCR4+CCR6+ (TH17) TEM Cells Concomitant with a Decreased CCR3+CCR4+CCR6+ (TH1) TEM Cells”

10:00–10:30 TEA/COFFEE

10:30–12:15: PARALLEL SESSION 7 (Auditorium)
OVERLAP AUTOIMMUNE DISEASE
Chairs: Neil Turner & Jan Willem-Cohen-Tervaert

10:30–11:00 Christopher Denton “Vasculitis in Overlap Autoimmune Rheumatic Disease”

11:00–11:15 O41: D. Cornc “ANCA-Associated Vasculitis in Patients with Primary Sjögren’s Syndrome: Detailed Analysis of 6 New Cases and 15 Cases from the Literature”

11:30–11:45 O42: T. Turner-Stokes “Positive ANCA Serology in Patients with Lupus Nephritis Is Associated with Different Histopathological Features on Renal Biopsy”

11:45–12:00 O43: G. Ennini “First Report of FIP1L1-PDGFRa-Positive EosinophilicGranulomatosis with Polangitis”

12:00–12:15 O44: M. Segelmark “IgA PR3-ANCA in Rheumatoid Arthritis is Related to Anti-CCP Antibodies and Chronic Inflammatory Response”

12:00–12:15 O45: S. McAdoo “Double Seropositivity for ANCA and Anti-GBM Antibodies: Clinical Characteristics and Outcomes of a Multi-centre European Cohort”

10:30–12:15: PARALLEL SESSION 8 (Rooms B&C)
PATHOGENIC MECHANISMS IN AAV
Chairs: Michael Robson & Marien Segelmark

10:30–11:00 Veronique Fremeaux-Bacchi “Complement and ANCA-Associated Vasculitis: From Marine Model to Clinical Trial”

11:00–11:15 O46: A. Roccellabianca “A defect in NADPH Oxidase Activity in Neutrophils from Granulomatosis with Polangitis Patients May Impair the Resolution of Inflammation”

11:30–11:45 O47: S. Henderson “Proteinase-3 (PR3) and Myeloperoxidase (MPO) Induce Granuloma Formation in ANCA-Associated Vasculitis (AAV)”

12:00–12:15 O48: G. Emonti “First Report of FIP1L1-PDGFRα-Positive Eosinophilic Granulomatosis with Polyangitis”

12:00–12:15 O49: A. Schreiber “Neutrophil-Gelatinase Associated Lipocalin (NGAL) Attenuates ANCA-Induced Glerulonephritis by Inhibiting Th17 Immunity”

12:00–12:15 O50: R. Popat “A Protective Role for the Lectin Pathway in Anti-Myeloperoxidase Vasculitis”

10:30–12:15: PARALLEL SESSION 9 (Room A)
RARE FORMS OF VASCULITIS
Chairs: John Stone & Paul Brogan

10:30–11:00 Ivona Aksamitjevich “Discovery of a Monogenic ANCA-Negative Vasculitis and/or Vasculopathy: Deficiency of ADA2 (DADA2)”

11:00–11:30 Augusto Vaglio “An Update on IgG4 Disease”

11:30–11:45 O51: S. Nanthapisal “Monogenic Polyarteritis Nodosa Caused by ADA2 Deficiency: The GOSH Experience”

12:00–12:15 O52: S. Nanthapisal “Monogenic Polyarteritis Nodosa Caused by ADA2 Deficiency: The GOSH Experience”

12:20–13:35 LUNCHTIME SYMPOSIUM sponsored by Roche (Auditorium)
B-Cell Therapy in Adult Patients with Severe, Active GPA and MPA
Chairs: Alan Salama & Charles Pusey
12:20–12:45 John Niles “Mabthera in Relapsing GPA/MPA Disease, Effects on ANCA and Immunoglobulin Levels”
12:45–13:10 Lorraine Harper “Managing Infectious Complications with Mabthera Treatment for GPA/MPA”
13:10–13:35 David Jayne “Mabthera Treatment for Severe GPA/MPA Renal Disease”

CLINICAL ASPECTS OF LVV
Chairs: Justin Mason & Eric Matteson

13:45–14:15 Peter Merkel “Diagnosis and Management of Large Vessel Vasculitis”

14:15–14:30 O53: Z. Wallace “Rituximab in IgG4-Related Disease (IgG4-RD): A Large Single Center Experience”

14:45–15:00 O54: D. Nakagomi “Including Image Assessment in Outcome Measure Development for Large Vessel Vasculitis”

14:30–14:45 O55: M. Koster “Glucocorticoid Use and Associated Complications in a Cohort of Patients with Biopsy-Proven Giant Cell Arteritis”

15:00–15:15 O56: N. Khalidi “Venothromboembolism in Large Vessel Vasculitis”

14:15–14:30 O57: D. Bunch “Gleaning Relapse Risk from B Cell Phenotype: Decreased CD5+ B Cells Portend a Shorter Time to Relapse After B Cell Depletion in Patients with ANCA Vasculitis”

14:45–15:00 O58: S. McAdoo “Double Seropositivity for ANCA and Anti-GBM Antibodies: Clinical Characteristics and Outcomes of a Multi-centre European Cohort”

VIII
Nephron 2015;129(suppl 2):VI–XII
DOI: 10.1159/000381119

Programme
Continuing Progress in Vasculitis Research

Nephron 2015;129(suppl 2):VI–XII

DOI: 10.1159/000381119
10:30–12:15: PARALLEL SESSION 14 (Rooms B&C)

INFLAMMATION IN AAV

Chairs: Coen Stegeman & Ming-Hui Zhao

10:30–11:00

**Thomas Hellmark** “Inflammatory Mechanisms in AAV”

11:00–11:15

**O82**: K. Martin “Proteinase 3 Affects the Production and Function of Microparticles: Implications for Inflammation and Autoimmune Vasculitis”

**O83**: R. Pepper “The Association of Serum Calprotectin (S100A8/S100A9) Levels with Disease Relapse in PR3-ANCA-Associated Vasculitis”

11:30–11:45

**O84**: R. Cartin-Ceba “Association of Fc Gamma Receptor Polymorphisms and Outcomes in Patients with ANCA-Associated Vasculitis Treated with Rituximab”

**O85**: A. Salmela “Nasal Carriage of Staphylococcus Aureus Does Not Influence Relapse in NORAM and CYCAZAREM Patients”

12:00–12:15

**O86**: P. Brunetta “The Role of Baseline FCRL5 MRNA Expression in Predicting Response to Rituximab (RTX) Therapy in Patients with Granulomatous Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)”

10:30–12:15: PARALLEL SESSION 15 (Room A)

COMPLICATIONS OF TREATMENT

Chairs: Marion Haubitz & Ulrich Specks

10:30–11:00

**Kerstin Westman** “Overview of Complications from AAV Treatment”

11:00–11:15

**O87**: A. Mohammad “Incidence and Impact of Severe Infections in ANCA-Associated Vasculitis – A Population-Based Study from Southern Sweden”

**O88**: F. Cortazar “Debunking the Myth of Hypogammaglobulinemia: ANCA Associated Vasculitis Patients Who Were Treated with Long Term B Cell Depletion with Rituximab”

11:30–11:45

**O89**: C. Heijl “First Occurrence of Malignancy in Patients Treated for Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Follow-Up Data from a Population Based Cohort in Southern Sweden”

**O90**: A. Hessels “Thiopurine Methyltransferase (TPMT) Genotype and Activity Do Not Predict Relapse Rates and Adverse Events in Antineutrophil Cytoplasmic Antibody Associated Vasculitis Patients Treated with Azathioprine Maintenance Therapy”

12:00–12:15

**O91**: D. Chanouzas “Increase in Adverse Events with Pulsed Methylprednisolone Used for Induction of Remission in Severe ANCA Associated Vasculitis”

12:15–13:30 LUNCH

13:30–15:00: PLENARY SESSION 6 (Auditorium)

EPIDEMIOLOGY OF VASCULITIS

Chairs: Richard Watts and Raashid Luqmani

13:30–14:00

**Alfred Mahr** “Environmental Effects and Risk of Vasculitis: Review of the Evidence and Research Agenda”

14:00–14:15

**O92**: J. Snazjd “Predictors of Delay in Diagnosis of Giant Cell Arteritis and Antineutrophil Cytoplasm Antibody-Associated Vasculitides – Analysis of Data from the Diagnostic and Classification Criteria in Vasculitis Study (DCVAS)”

**O93**: Z. Wallace “Improved Survival in Granulomatosis with Polyangiitis: A General Population-Based Study”

14:30–14:45

**O94**: M. Piram “Kawasaki Disease in France (KAWANET): Incomplete Forms Are Frequent and Associated with a High Frequency of Cardiac Complications”

**O95**: F. Pearce “Ethnic and Geographic Differences in the Phenotype of ANCA Associated Vasculitis (AAV) – Preliminary Data from the DCVAS Study”

15:00–15:30 TEA/COFFEE

15:30–16:15 (Auditorium)

CLOSING LECTURE

Chairs: Peter Merkel & Alan Salama

**David Jayne** “Ongoing and future vasculitis studies”

16:15–16:30 Prize giving – Niels Rasmussen

16:30–16:45 Closing remarks – Charles Pusey
**MODERATED POSTER SESSION (1)**  
**MONDAY 19 APRIL: 15:00–16:00**  
**LARGE VESSEL VASCULITIS**  
Chairs: Maria Cid & Justin Mason

- **P1.** A. Lo Gullo “Venous Thromboembolic and Cerebrovascular Events in Giant Cell Arteritis: A Population-Based Cohort Study”
- **P3.** M. Twilt “Recognition of Antibody-Mediated Inflammatory Brain Diseases in Children: A Single Center Cohort Study”
- **P5.** M. Becatti “NADPH Oxidase Is a Source of Oxidative Stress in White Blood Cells of Behçet’s Patients”
- **P7.** S. Unizony “Acute Phase Reactants and Their Correlation with Clinical Activity in ANCA-Associated Vasculitis”
- **P8.** N. Medjeral-Thomas “Disease-Free Remission Following Rituximab and Low-Dose Cyclophosphamide Therapy for Renal ANCA-Associated Vasculitis: Long-Term Follow-Up”
- **P10.** Z. Hruskova “Long-Term Outcome of Patients with ANCA-Associated Vasculitis Treated with Plasma Exchange: A Retrospective Single Centre Study”
- **P12.** A. Bruchfeld “Fatal Adenovirus Hepatitis After Rituximab Therapy for ANCA-Associated Vasculitis”
- **P14.** S. McAadoo “Ofatumumab for B Cell Depletion Therapy in ANCA-Associated Vasculitis”

**TREATMENT OF AAV**  
Chairs: Richard Kitching & Mark Little

- **P9.** D. Harland “MabThera® (Rituximab) for the Treatment of Severe Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) – A Cost-Utility Model for the United Kingdom”
- **P11.** A. Casian “Rituximab and Vascular Function in ANCA Associated Vasculitis”
- **P13.** R. Smith “RITAZAREM: An International, Open-Label, Randomised Controlled Trial Comparing Rituximab with Azathioprine as Maintenance Therapy in Relapsing ANCA-Associated Vasculitis”

**RELAPSES IN AAV**  
Chairs: Min Chen & Lorraine Harper

- **P15.** S. Brix “CCL18 in Relapsing ANCA-Associated Necrotizing Glomerulonephritis”
- **P17.** L. Fussner “Predictive Value of a Rise in PR3-ANCA for Relapse After Complete Remission in Severe ANCA-Associated Vasculitis”
- **P19.** B. Dumogü “Impact of Cardiac Magnetic Resonance Imaging on Eosinophilic Granulomatosis with Polyangiitis Outcomes: A Long-Term Retrospective Study of 42 Patients”
- **P21.** R. Pepper “B Cell Subsets Associated with Poor Response to Rituximab in ANCA Associated Vasculitis”

**ANCA DETECTION AND ASSOCIATIONS**  
Chairs: Caroline Savage & Ulrich Specks

- **P22.** F. Pearce “The Association Between ANCA Antibodies and Thyroid Disease Is Independent of ANCA-Associated Vasculitis”
- **P24.** N. Rodriguez “Association of Inflammatory Bowel Disease with Anti-PR3 and MPO Antibodies”
- **P26.** L. Holm “Classical and Alternative Pathway in ANCA-Associated Vasculitis”
- **P28.** L. Hinkofer “PR3-ANCA in GPA Partially Inhibit and Sometimes Stimulate PR3 Activity, But Do Not Predict Relapse or Disease Progression”

**MODERATED POSTER SESSION (2)**  
**TUESDAY 20 APRIL: 15:15–16:15**  
**ASSESSMENT OF LVV**  
Chairs: Luis-Felipe Flores-Suarez & John Stone

- **P29.** A. Gul “Acute Phase Reactants and Their Correlation with Clinical Activity in Behçet’s Disease”
- **P31.** A. Sreih “Damage Assessment in Takayasu’s Arteritis”
- **P33.** E. Brouwer “Serum Markers Associated with Disease Activity in Giant Cell Arteritis and Polymyalgia Rheumatica”
- **P35.** E. Tombett “Novel MRI-Based Longitudinal Scoring of Arterial Involvement in Large-Vessel Vasculitis”
- **P30.** H. Direskeneli “Assessment of Disease Activity in Large Vessel Vasculitis: Results of an International Delphi Exercise”
- **P32.** A. Serafin “Early Halo Sign Features on Ultrasound Examination of Treated Patients with Giant Cell Arteritis”
- **P34.** A. Diamantopoulos “A Head-to-Head Comparison of Color Doppler Ultrasonography and Magnetic Resonance Angiography in Patients with Systemic Large Vessel Vasculitis”

**Continuing Progress in Vasculitis Research**

Nephron 2015;129(suppl 2):VI–XII

DOI: 10.1159/000381119
### OUTCOMES OF VASCULITIS

**Chairs:** Paul Brogan & Michael Venning

| P36 | A. Neel “Prognosis Value of Geriatric Assessment Scales in Older Adult with New Onset ANCA-Associated Vasculitis: A Pilot Retrospective Study” |
| P37 | S. Kamali “A Very High Prevalence of Avascular Necrosis in Turkish Patients with Granulomatosis with Polyangiitis (Wegener’s): Preliminary Results from a Single Centre” |
| P40 | N. Brown “A Delphi Study for Assessing Prevention of Disease and Treatment Related Morbidities in ANCA Associated Vasculitis (ADAPTIV)” |
| P42 | D. Indrakanti “Association of Cytochrome P450 Polymorphisms and Outcomes in Patients with ANCA-Associated Vasculitis Treated with Cyclophosphamide” |

### EPIDEMIOLOGY OF VASCULITIS

**Chairs:** Kerstin Westman & Richard Watts

| P43 | A. Mohammad “Rate of Co-Morbidities in ANCA Associated Vasculitis – A Population-Based Study” |
| P44 | S. Furuta “Comparison of the Phenotype and Outcomes of Granulomatosis with Polyangiitis (GPA) in the US” |
| P45 | K. Raimundo “Clinical and Economical Burden of Granulomatosis with Polyangiitis (GPA) in the US” |
| P46 | B. Terrier “Granulomatosis with Polyangiitis (Wegener’s) According to Geographic Origin and Ethnicity: Clinical-Biological Presentation and Outcome” |
| P47 | H. Pearlman “Renal and Extra Renal Outcomes in ANCA Negative and ANCA Positive Small Vessel Vasculitis” |
| P49 | M. Piram “Epidemiological Features of Childhood IgA Vasculitis (IgAV, Henoch-Schönlein) in a French County: A Population-Based Survey” |

### IMMUNITY IN AAV

**Chairs:** Ralph Kettritz & Michael Robson

| P50 | N. Brown “A Description of Infection and Vaccination in Patients with Granulomatosis with Polyangiitis, Using the Clinical Practice Research Database” |
| P51 | D. Chanouzas “CD4+CD28- T-Cell Expansions in ANCA-Associated Vasculitis are Associated with Arterial Stiffness” |
| P52 | B. Wilde “IL-22 Producing T-Helper-Cells Are Expanded in ANCA-Associated Vasculitis” |
| P53 | M. Morgan “Poor Vaccine Responses Predict Mortality in an Immunosuppressed Population” |
| P54 | E. Callery “ANCA-Associated Vasculitis Patients Receiving Immunosuppressive Therapy, Correlation between the Reconstitution of CMV-Specific CD8+ T Cells and Patient Outcome” |
| P55 | A. Neel “Latent CMV Infection Drives TEMRA Expansion in ANCA-Associated Vasculitides But Has No Impact on Disease Presentation Nor on Outcome” |
| P56 | N. Brown “Measurement of Plasma micro-RNA 155 in ANCA Associated Vasculitis” |